Patents by Inventor Thomas Steuber

Thomas Steuber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of detecting proteins in human samples and uses of such methods
    Patent number: 11320435
    Abstract: A method for collecting information about the health status of a subject is proposed involving the quantitative detection, in serum, plasma or blood of the subject, of the concentration of THBS1, the proportion of free PSA (% fPSA), preferably including the concentration of at least one protein selected from the group consisting of CTSD, OLFM4, ICAM1.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: May 3, 2022
    Assignee: ProteoMedix AG
    Inventors: Ralph Schiess, Kathrin Endt, Alcibiade Athanasiou, Annalisa Macagno, Thomas Steuber
  • METHOD OF DETECTING PROTEINS IN HUMAN SAMPLES AND USES OF SUCH METHODS
    Publication number: 20190250163
    Abstract: A method for collecting information about the health status of a subject is proposed involving the quantitative detection, in serum, plasma or blood of the subject, of the concentration of THBS1, the proportion of free PSA (% fPSA), preferably including the concentration of at least one protein selected from the group consisting of CTSD, OLFM4, ICAM1.
    Type: Application
    Filed: July 11, 2017
    Publication date: August 15, 2019
    Applicant: ProteoMedix AG
    Inventors: Ralph SCHIESS, Kathrin ENDT, Alcibiade ATHANASIOU, Annalisa MACAGNO, Thomas STEUBER
  • CIRCULATING miRNAs AS NON-INVASIVE MARKERS FOR DIAGNOSIS AND STAGING IN PROSTATE CANCER
    Publication number: 20120264638
    Abstract: The present invention relates to a method for staging prostate cancer in a subject suffering from prostate cancer, said method comprises (a) determining the amount of at least one miRNA selected from the group consisting of miRNA-375, miRNA-141, miRNA-200b, miRNA-516a-3p and miRNA9*, or the amount of a precursor molecule in a sample from said patient and (b) comparing the, thus, determined amount with a reference amount. Moreover, the present invention is concerned with a method for identifying a subject susceptible to prostate cancer therapy and to a method for diagnosing prostate cancer. Further envisaged by the present invention are a kit and a device adapted to carry out the method of the present invention.
    Type: Application
    Filed: October 29, 2010
    Publication date: October 18, 2012
    Inventors: Jan Christoph Brase, Holger Sültmann, Ruprecht Kuner, Marc Johannes, Tim Beissbarth, Maria Fälth, Thorsten Schlomm, Alexander Haese, Thomas Steuber